Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

In contrast to PARP1 and PARP2, neither PARP10 nor the predicted PARP-family mART enzymes are thought to be activated by DNA damage. In fact—at least in vitro—DNA reduces PARP10 activity 7.

PARP-1 is an enzyme directly involved in repairing single-stranded DNA breaks. It senses single-stranded DNA breaks through a zinc-finger DNA-binding domain, binds to the sites of breaks and ...

PARP inhibitors target the DDR PARP enzymes support single strand break repair and prevent formation of DNA double strand breaks (DSBs) during replication. Repair of these DSBs requires homologous ...

Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. TALZENNA ...

Preclinical studies have demonstrated that Talzenna blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. Talzenna was ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with ...